|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.95 USD | +10.44% |
|
+23.20% | +44.15% |
| Apr. 23 | BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating | MT |
| Mar. 12 | Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating | MT |
Jan 8 (Reuters) - LifeMD Inc:
* LIFEMD PROVIDES 2024 FINANCIAL GUIDANCE
* LIFEMD INC : 2024 REVENUE TO BE BETWEEN $195 AND $205 MILLION
* LIFEMD INC : 2024 ADJUSTED EBITDA TO BE BETWEEN $18 AND $22 MILLION
* LIFEMD INC : POSITIVE FULL-YEAR FREE CASH FLOW WITH YEAR-END 2023 CASH EXCEEDING $30 MILLION Source text for Eikon: Further company coverage:
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 10,732 PTS | +2.39% | +4.30% | - | ||
| 11.95 USD | +10.44% | +23.20% | 482M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +44.15% | 482M | |
| +4.36% | 32.47B | |
| +14.14% | 7.45B | |
| +22.93% | 3.89B | |
| -16.29% | 3.15B | |
| -25.96% | 1.28B | |
| -36.14% | 1.09B | |
| -0.13% | 893M | |
| -35.42% | 902M | |
| -24.12% | 857M |
LIFEMD, INC. 
